+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Adalimumab"

From
Market Spotlight: Axial Spondyloarthritis (axSpA) - Product Thumbnail Image

Market Spotlight: Axial Spondyloarthritis (axSpA)

  • Report
  • March 2021
  • 52 Pages
  • Global
Market Spotlight: Psoriatic Arthritis - Product Thumbnail Image

Market Spotlight: Psoriatic Arthritis

  • Report
  • September 2020
  • 65 Pages
  • Global
From
KOL Perspectives: Upadacitinib for Rheumatoid Arthritis - Product Thumbnail Image

KOL Perspectives: Upadacitinib for Rheumatoid Arthritis

  • Report
  • August 2018
  • 24 Pages
  • Global
From
From
AbbVie Hit Harder By EU Humira Biosimilars Than Projected - Product Thumbnail Image

AbbVie Hit Harder By EU Humira Biosimilars Than Projected

  • Newsletter
  • May 2024
  • 3 Pages
  • Europe
From
Rheumatoid Arthritis Market and Forecast Analysis to 2025 - Product Thumbnail Image

Rheumatoid Arthritis Market and Forecast Analysis to 2025

  • Drug Pipelines
  • August 2018
  • 610 Pages
  • Global
From
Humira - Product Thumbnail Image

Humira

  • Report
  • August 2018
  • 94 Pages
  • Global
From
Psoriatic Arthritis Market and Forecast Analysis 2035 - Product Thumbnail Image

Psoriatic Arthritis Market and Forecast Analysis 2035

  • Drug Pipelines
  • July 2018
  • 503 Pages
  • Global
From
Global and Chinese Adalimumab Industry, 2021 Market Research Report - Product Thumbnail Image

Global and Chinese Adalimumab Industry, 2021 Market Research Report

  • Report
  • January 2021
  • 138 Pages
  • China, Global
From
Loading Indicator

Adalimumab is a biologic drug used to treat a variety of immune disorders, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and juvenile idiopathic arthritis. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Adalimumab is administered by subcutaneous injection and is available in both brand-name and generic forms. Adalimumab is one of the most widely prescribed drugs for immune disorders, and it has been approved for use in more than 100 countries. It is a highly effective treatment for many of the conditions it is used to treat, and it has been shown to improve quality of life for patients. Some of the companies in the Adalimumab market include AbbVie, Amgen, Biogen, Boehringer Ingelheim, Janssen Biotech, Merck, and Pfizer. Show Less Read more